Last reviewed 2026-04-19 · How we verify

BT-007 CD7 CAR-T cells

Bioceltech Therapeutics, Ltd. · Phase 1 active Biologic

BT-007 CD7 CAR-T cells is a Biologic drug developed by Bioceltech Therapeutics, Ltd.. It is currently in Phase 1 development.

At a glance

Generic name	BT-007 CD7 CAR-T cells
Sponsor	Bioceltech Therapeutics, Ltd.
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BT-007 CD7 CAR-T cells CI brief — competitive landscape report
BT-007 CD7 CAR-T cells updates RSS · CI watch RSS
Bioceltech Therapeutics, Ltd. portfolio CI

Frequently asked questions about BT-007 CD7 CAR-T cells

What is BT-007 CD7 CAR-T cells?

BT-007 CD7 CAR-T cells is a Biologic drug developed by Bioceltech Therapeutics, Ltd..

Who makes BT-007 CD7 CAR-T cells?

BT-007 CD7 CAR-T cells is developed by Bioceltech Therapeutics, Ltd. (see full Bioceltech Therapeutics, Ltd. pipeline at /company/bioceltech-therapeutics-ltd).

What development phase is BT-007 CD7 CAR-T cells in?

BT-007 CD7 CAR-T cells is in Phase 1.

Manufacturer: Bioceltech Therapeutics, Ltd. — full pipeline
Compare: BT-007 CD7 CAR-T cells vs similar drugs
Pricing: BT-007 CD7 CAR-T cells cost, discount & access